Abbott Takes Advantage Of China Health-Reform Effort To Sell Diagnostics
This article was originally published in PharmAsia News
Executive Summary
Abbott Laboratories expects to have 33 diagnostics approved for the China market by the end of the year, helping the U.S.-based company gain a foothold in a market where a five-year health-care reform plan relies on more diagnoses.